The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Active surveillance for the management of prostate cancer in a contemporary cohort
Open accessAbstract
BACKGROUND.: Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for select patients with early‐stage prostate cancer. In this article, the authors report their experience in a contemporary cohort of men with prostate cancer who were managed with active surveillance. METHODS.: All men who were managed initially with active surveillance were identified through the authors' institutional database. Selection criteria for active surveillance included: prostate‐specific antigen (PSA) <10 ng/mL, biopsy Gleason sum ≤6 with no pattern 4 or 5, cancer involvement of <33% of biopsy cores, and clinical stage T1/T2a tumor. Patients were followed with PSA measurements and digital rectal examination every 3 to 6 months and with transrectal ultrasound at 6‐ to 12‐month intervals. Beginning in 2003, patients also underwent repeat prostate biopsy at 12 to 24 months. The primary outcome measured was active treatment. Evidence of disease progression, defined as an increase in rebiopsy Gleason sum or significant PSA velocity changes (>0.75 ng/mL per year), was a secondary outcome. Chi‐square and log‐rank tests were used to compare groups. The association between clinical characteristics and receipt of active treatment was analyzed by using Cox proportional hazards regression. RESULTS.: Three hundred twenty‐one men (mean age [±standard deviation]: 63.4 ± 8.5 years) selected active surveillance as their initial management. The overall median follow‐up was 3.6 years (range, 1–17 years). The initial mean PSA level was 6.5 ± 3.9 ng/mL. One hundred twenty men (37%) met at least 1 criterion for progression. Overall, 38% of men had higher grade on repeat biopsy, and 26% of men had a PSA velocity >0.75 ng/mL per year. Seventy‐eight men (24%) received secondary treatment at a median 3 years (range, 1–17 years) after diagnosis. Approximately 13% of patients with no disease progression elected to obtain treatment. PSA density at diagnosis and rise in Gleason score on repeat biopsy were associated significantly with receipt of secondary treatment. The disease‐specific survival rate was 100%. CONCLUSIONS.: Selected individuals with early‐stage prostate cancer may be candidates for active surveillance. Specific criteria can be and need to be developed to select the most appropriate individuals for this form of management and to monitor disease progression. A small attrition rate can be expected because of men who are unable or unwilling to tolerate surveillance. Cancer 2008. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,358
Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy
D'Amico, A. V., Chen, M.-H., Roehl, K. A., & Catalona, W. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032975 · Cited by 740
Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer
Albertsen, P. C. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530080042039 · Cited by 464
COOPERBERG, M. R., BROERING, J. M., LITWIN, M. S., LUBECK, D. P., MEHTA, S. S., HENNING, J. M., CARROLL, P. R., & the CaPSURE INVESTIGATORS (2004) · Journal of Urology · doi:10.1097/01.ju.0000107247.81471.06 · Cited by 340
Self-citationNational Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.981 · Cited by 329
Self-citationLitwin, M. S., Gore, J. L., Kwan, L., Brandeis, J. M., Lee, S. P., Withers, H. R., & Reiter, R. E. (2007) · Cancer · doi:10.1002/cncr.22676 · Cited by 249
Latini, D. M., Hart, S. L., Knight, S. J., Cowan, J. E., Ross, P. L., DuChane, J., Carroll, P. R., & CaPSURE Investigators (2007) · Journal of Urology · doi:10.1016/j.juro.2007.05.039 · Cited by 223
Self-citationDelayed Versus Immediate Surgical Intervention and Prostate Cancer Outcome
Warlick, C., Trock, B. J., Landis, P., Epstein, J. I., & Carter, H. B. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj072 · Cited by 219
Potosky, A. L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.6.430 · Cited by 195
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Active Surveillance for Prostate Cancer: A Systematic Review of the Literature
Dall’Era, M. A., Albertsen, P. C., Bangma, C., Carroll, P. R., Carter, H. B., Cooperberg, M. R., Freedland, S. J., Klotz, L. H., Parker, C., & Soloway, M. S. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.072 · Cited by 602
Self-citationActive Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience
Tosoian, J. J., Trock, B. J., Landis, P., Feng, Z., Epstein, J. I., Partin, A. W., Walsh, P. C., & Carter, H. B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8112 · Cited by 596
Turkbey, B., Shah, V. P., Pang, Y., Bernardo, M., Xu, S., Kruecker, J., Locklin, J., Baccala, A. A., Rastinehad, A. R., Merino, M. J., et al. (2011) · Radiology · doi:10.1148/radiol.10100667 · Cited by 389
Hambrock, T., Hoeks, C., Hulsbergen-van de Kaa, C., Scheenen, T., Fütterer, J., Bouwense, S., van Oort, I., Schröder, F., Huisman, H., & Barentsz, J. (2012) · European Urology · doi:10.1016/j.eururo.2011.08.042 · Cited by 307
Metadata
- Authors
- Dall'Era, M. A., Konety, B. R., Cowan, J. E., Shinohara, K., Stauf, F., Cooperberg, M. R., Meng, M. V., Kane, C. J., Perez, N., Master, V. A., & Carroll, P. R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-04-23
- Volume
- 112
- Issue
- 12
- Pages
- 2664-2670
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2149339272
- Cited by
- 404
- References
- 17
- FWCI
- 23.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Active surveillance for the management of prostate cancer in a contemporary cohort. https://app.cochat.ai/papers/10.1002/cncr.23502
- The paper
- Dall'Era, M. A., Konety, B. R., Cowan, J. E., Shinohara, K., Stauf, F., Cooperberg, M. R., Meng, M. V., Kane, C. J., Perez, N., Master, V. A., & Carroll, P. R. (2008). Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. https://doi.org/10.1002/cncr.23502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.